HK1208159A1 - Sorcs1 for use in the treatment of obesity and overweight sorcs1 - Google Patents

Sorcs1 for use in the treatment of obesity and overweight sorcs1

Info

Publication number
HK1208159A1
HK1208159A1 HK15108775.7A HK15108775A HK1208159A1 HK 1208159 A1 HK1208159 A1 HK 1208159A1 HK 15108775 A HK15108775 A HK 15108775A HK 1208159 A1 HK1208159 A1 HK 1208159A1
Authority
HK
Hong Kong
Prior art keywords
sorcs1
overweight
obesity
treatment
overweight sorcs1
Prior art date
Application number
HK15108775.7A
Other languages
English (en)
Chinese (zh)
Inventor
Karen-Marie Pedersen
Anders Nykjr
Mads Fuglsang Kjby
Original Assignee
Univ Aarhus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Aarhus filed Critical Univ Aarhus
Publication of HK1208159A1 publication Critical patent/HK1208159A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK15108775.7A 2012-04-17 2015-09-09 Sorcs1 for use in the treatment of obesity and overweight sorcs1 HK1208159A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201270191 2012-04-17
PCT/DK2013/050107 WO2013156031A2 (en) 2012-04-17 2013-04-17 SorCS1 FOR USE IN THE TREATMENT OF OBESITY AND OVERWEIGHT

Publications (1)

Publication Number Publication Date
HK1208159A1 true HK1208159A1 (en) 2016-02-26

Family

ID=49384162

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108775.7A HK1208159A1 (en) 2012-04-17 2015-09-09 Sorcs1 for use in the treatment of obesity and overweight sorcs1

Country Status (10)

Country Link
US (1) US20150166629A1 (xx)
EP (1) EP2874646A4 (xx)
JP (1) JP2015514726A (xx)
CN (1) CN104470532A (xx)
AU (1) AU2013248727A1 (xx)
CA (1) CA2870211A1 (xx)
HK (1) HK1208159A1 (xx)
IL (1) IL235066A0 (xx)
SG (1) SG11201406455YA (xx)
WO (1) WO2013156031A2 (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105136781B (zh) * 2015-08-13 2018-03-30 上海交通大学医学院附属瑞金医院 脂肪因子grem2作为药物靶点在治疗肥胖症药物中的应用
EP3666281A1 (en) 2018-12-14 2020-06-17 Insusense ApS Compositions comprising sortilin-1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223392A (en) * 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
AT404357B (de) * 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
AR027509A1 (es) * 2000-01-10 2003-04-02 Maxygen Aps Conjugados g-csf
AU2003268519A1 (en) * 2002-09-09 2004-03-29 Wisconsin Alumni Research Foundation Type 2 diabetes susceptibility genes
DK2120997T3 (en) * 2006-12-21 2017-05-08 H Lundbeck As MODULATION OF PRO-NEUROTROPHIN ACTIVITY
EP2008666A1 (en) * 2007-06-29 2008-12-31 Institut Pasteur Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications
US9101117B2 (en) * 2009-06-10 2015-08-11 Aarhus Universitet SorCS1-like agent for use in the treatment of insulin resistance and diseases related thereto

Also Published As

Publication number Publication date
EP2874646A2 (en) 2015-05-27
CA2870211A1 (en) 2013-10-24
US20150166629A1 (en) 2015-06-18
CN104470532A (zh) 2015-03-25
JP2015514726A (ja) 2015-05-21
WO2013156031A2 (en) 2013-10-24
WO2013156031A3 (en) 2013-12-12
EP2874646A4 (en) 2016-07-06
AU2013248727A1 (en) 2014-11-06
IL235066A0 (en) 2014-12-31
SG11201406455YA (en) 2014-11-27

Similar Documents

Publication Publication Date Title
IL282128A (en) Methods for treating overweight and obesity
HK1216176A1 (zh) 用於治療增殖性和自身免疫疾病的非對稱吡咯並苯並二氮雜卓二聚物
IL237125A0 (en) Use of preparations containing niclosamide and/or its derivatives for the treatment of solid tumors
HK1207860A1 (en) 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders 2--5---2h--3-
HRP20181879T1 (hr) Spojevi za liječenje pretilosti i postupci za njihovu upotrebu
HK1211221A1 (en) Formulations for the treatment and prevention of obesity
HK1209639A1 (en) Gpbp-1 inhibition and its therapeutic use gpbp-1
ZA201501503B (en) Bio-inoculant and use thereof for treatment of effluents
IL233875A (en) Preparation and use for the treatment of anal fissures
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
LT2845598T (lt) Preparatas, skirtas naudoti netipinės osteoporozės prevencijai ir gydymui
EP2744786A4 (en) SUBSTITUTED 2-IMIDAZOLIDINONE AND 2-IMIDAZOLONE AND THEIR USE IN THE TREATMENT OF CANCER
HK1208159A1 (en) Sorcs1 for use in the treatment of obesity and overweight sorcs1
ZA201503266B (en) Pyidone derivatives and uses thereof in the treatment of tuberculosis
ZA201401800B (en) Novel plant defensins and use in the treatment of proliferative diseases
SI2663185T1 (sl) Calebin A za uporabo pri zdravljenju vnetja in debelosti
PT2389936E (pt) Aminaftona para utilização no tratamento e/ou prevenção de enxaqueca
GB201117876D0 (en) Peptides and their use in treatment
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer